Kamiren hl pills 4mg №30

Dosage form

Modified Release Tablets

Composition

1 modified-release pill contains the active substance Doxazosin mesilate 4.85 mg (corresponding to 4 mg doxazosin).
Excipients: hypromellose, anhydrous Calcium phosphate, lactose monohydrate, Magnesium stearate; shell: Opadry white dye - hypromellose, titanium dioxide (E 171), Macrogol 400.

Packaging

30 pieces

Mechanism of action

Doxazosin is a selective competitive blocker of postsynaptic alpha1-adrenergic receptors. By reducing the muscle tone of the blood vessels, doxazosin reduces total peripheral vascular resistance, which leads to a decrease in blood pressure (BP). After a single dose of the drug, the maximum of the hypotensive effect is observed in the period from 2 to 6 hours, and in general, the hypotensive effect lasts for 24 hours. In the period of treatment with doxazosin in patients with arterial hypertension, there are no differences in the values ​​of blood pressure in the standing and lying positions.
Effective with arterial hypertension, including, accompanied by metabolic disorders (obesity, decreased glucose tolerance).
Reduces the risk of coronary heart disease.
Taking the drug in individuals with normal blood pressure (BP) is not accompanied by a decrease in blood pressure. With prolonged use of doxazosin in patients there is no change in tolerance to a therapeutic antihypertensive effect.
During treatment with doxazosin, a decrease in plasma plasma levels of triglycerides, total cholesterol, is observed. At the same time, there is some (by 4–13%) increase in the HDL / total cholesterol ratio.
With long-term treatment with doxazosin, there is regression of left ventricular hypertrophy, suppression of platelet aggregation and an increase in the content of active plasminogen in the tissues.
Due to the fact that doxazosin blocks alpha1-adrenergic receptors located in the stroma and capsule of the prostate gland and in the bladder neck, there is a decrease in resistance and pressure in the urethra, a decrease in resistance of the internal sphincter. Therefore, the administration of doxazosin to patients with symptoms of benign prostatic hyperplasia leads to a significant improvement in urodynamic indicators and a decrease in the manifestations of symptoms of the disease. It has an effect in 66-71% of patients, the onset of action after 1-2 weeks of treatment, the maximum after 14 weeks, the effect lasts for a long time. Compared with the drug in pills and the drug in the dosage form of a modified release tablet, the latter improves the balance between efficacy and safety.Doxazosin is a selective competitive blocker of postsynaptic alpha1-adrenergic receptors. By reducing the muscle tone of the blood vessels, doxazosin reduces total peripheral vascular resistance, which leads to a decrease in blood pressure (BP). After a single dose of the drug, the maximum of the hypotensive effect is observed in the period from 2 to 6 hours, and in general, the hypotensive effect lasts for 24 hours. In the period of treatment with doxazosin in patients with arterial hypertension, there are no differences in the values ​​of blood pressure in the standing and lying positions.
Effective with arterial hypertension, including, accompanied by metabolic disorders (obesity, decreased glucose tolerance).
Reduces the risk of coronary heart disease.
Taking the drug in individuals with normal blood pressure (BP) is not accompanied by a decrease in blood pressure. With prolonged use of doxazosin in patients there is no change in tolerance to a therapeutic antihypertensive effect.
During treatment with doxazosin, a decrease in plasma plasma levels of triglycerides, total cholesterol, is observed. At the same time, there is some (by 4–13%) increase in the HDL / total cholesterol ratio.
With long-term treatment with doxazosin, there is regression of left ventricular hypertrophy, suppression of platelet aggregation and an increase in the content of active plasminogen in the tissues.
Due to the fact that doxazosin blocks alpha1-adrenergic receptors,located in the stroma and the capsule of the prostate gland and in the bladder neck, there is a decrease in resistance and pressure in the urethra, a decrease in resistance of the internal sphincter. Therefore, the administration of doxazosin to patients with symptoms of benign prostatic hyperplasia leads to a significant improvement in urodynamic indicators and a decrease in the manifestations of symptoms of the disease. It has an effect in 66-71% of patients, the onset of action after 1-2 weeks of treatment, the maximum after 14 weeks, the effect lasts for a long time. Compared with the drug in pills and the drug in the dosage form of a modified release tablet, the latter improves the balance between efficacy and safety.

Indications and usage

The drug is recommended for the treatment of arterial hypertension of mild or moderate severity (in combination with other antihypertensive drugs - thiazide diuretics, beta-blockers, slow calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors and for symptomatic treatment of benign prostatic hyperplasia.

Contraindications

Kamiren CL should not be prescribed to patients with hypersensitivity to doxazosin and other quinazoline derivatives (prazosin, terazosin) or to other components of the drug under the age of 18 years (efficacy and safety have not been established).
Use with caution in aortic or mitral stenosis, in patients with impaired liver and / or kidney function, orthostatic hypotension.

Pregnancy and Breastfeeding

Pregnant women can be prescribed the drug only for health reasons, when the benefits to the mother outweigh the potential risk to the fetus / child. The safety of the drug in infants has not been established, therefore, nursing mothers are advised to stop feeding during treatment with doxazosin.

Dosage and administration

Inside, 1 time per day (in the morning or in the evening), regardless of the meal, without chewing and drinking plenty of water.
The dose of the drug should be adjusted depending on the effectiveness of the drug or possible side effects in specific patients. Patients with hepatic impairment require smaller doses due to slow metabolism of the drug.
If the patient has forgotten to take the drug at the usual time, he should take the appropriate dose of the drug as soon as possible. If the time is right for taking the next dose, then you should only take it (without doubling the dose). It is important to take the drug regularly. If the patient has not taken the drug for several days, then the new therapeutic course should be started with the lowest dose.
Arterial hypertension: The usual dose of Kamiren CL is 1 pill (4 mg) per day. Its effect can be observed already on the first day, the therapeutic effect occurs 4 weeks after the start of treatment.After 4 weeks, in case of good tolerability of the drug and if the doctor deems the effect insufficient, higher doses can be prescribed. The maximum recommended daily dose of Kamiren CL is 2 pills (8 mg) in one dose.
If the therapeutic effect is not enough, patients can simultaneously receive other antihypertensive drugs: beta-blockers, diuretics, slow calcium channel blockers and ACE inhibitors.
After achieving a stable therapeutic effect, the dose is usually somewhat reduced (the average therapeutic dose with maintenance therapy is usually 2-4 mg per day), you can switch to CAMIRENA, pills 2 or 4 mg.
Benign prostatic hyperplasia in patients with normal blood pressure: the usual dose is 1 pill (4 mg) CAMIRENA CL per day. The patient should take the first dose in the evening before bedtime. Depending on the action of the drug, the dose can be gradually increased at intervals of 1-2 weeks to 8 mg once a day. As a rule, average daily doses range from 2 mg to 4 mg, you can switch to CAMIRENA, 2 or 4 mg tablets. The maximum daily dose is 8 mg.
Benign prostatic hyperplasia in patients with arterial hypertension: doses of the drug are the same as in the case of arterial hypertension without benign prostatic hyperplasia (see doses for arterial hypertension).
The drug is used for a long time.The duration of treatment is determined by the attending physician.

Arterial hypertension 
In clinical trials, orthostatic hypotension, which in rare cases can lead to fainting, has been observed most often, especially at the beginning of treatment.
General reactions: asthenia, fatigue, malaise.
Since the cardiovascular system: swelling, fainting.
Eliminating the alpha-adrenostimulating effects of epinephrine can lead to tachycardia and arterial hypotension.

Particular caution should be exercised in the appointment of this drug to patients with impaired liver function, especially in cases where at the same time use drugs that can adversely affect liver function. In cases of deterioration of the functional status of the liver, the drug is immediately canceled.
In order to prevent orthostatic reactions, patients should avoid unexpected and abrupt changes in body position (moving from the "lying" to the "standing" position).
Taking alcohol can increase undesirable reactions.
The safety and efficacy of doxazosin in children has not been established, therefore, it is not recommended to prescribe the drug to children.
The effect of the "first" administration of the drug is especially pronounced against the background of previous diuretic therapy and a sodium-restricted diet.
Before starting therapy, it is necessary to exclude a cancerous degeneration of the prostate gland.
Due to the fact that doxazosin can cause orthostatic reactions at the beginning of treatment or during the period of increasing dosages, it is advisable for patients to refrain from all potentially hazardous activities, in particular from driving vehicles and other vehicles and mechanisms.

In the dark place at a temperature of no higher than 25 ° C.